Publicación:
The world federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2012 on the long-term treatment of bipolar disorder

dc.contributor.authorGrunze, Heinz
dc.contributor.authorVieta, Eduard
dc.contributor.authorGoodwin, Guy M.
dc.contributor.authorBowden, Charles
dc.contributor.authorLicht, Rasmus W.
dc.contributor.authorMöller, Hans-Jürgen
dc.contributor.authorKasper, Siegfried
dc.date.accessioned2026-05-14T14:28:47Z
dc.date.issued2013
dc.description.abstractObjectives. These guidelines are based on a first edition that was published in 2004, and have been edited and updated with the available scientific evidence up to October 2012. Their purpose is to supply a systematic overview of all scientific evidence pertaining to the long-term treatment of bipolar disorder in adults. Methods. Material used for these guidelines are based on a systematic literature search using various data bases. Their scientific rigor was categorised into six levels of evidence (A-F) and different grades of recommendation to ensure practicability were assigned. Results. Maintenance trial designs are complex and changed fundamentally over time; thus, it is not possible to give an overall recommendation for long-term treatment. Different scenarios have to be examined separately: Prevention of mania, depression, or an episode of any polarity, both in acute responders and in patients treated de novo. Treatment might differ in Bipolar II patients or Rapid cyclers, as well as in special subpopulations. We identified several medications preventive against new manic episodes, whereas the current state of research into the prevention of new depressive episodes is less satisfactory. Lithium continues to be the substance with the broadest base of evidence across treatment scenarios. Conclusions. Although major advances have been made since the first edition of this guideline in 2004, there are still areas of uncertainty, especially the prevention of depressive episodes and optimal long-term treatment of Bipolar II patients. Copyright © 2013 Informa Healthcare.en_US
dc.identifier.doihttps://doi.org/10.3109/15622975.2013.770551
dc.identifier.scopus2-s2.0-84875148987
dc.identifier.urihttps://hdl.handle.net/20.500.12866/19718
dc.language.isoeng
dc.publisherInforma Healthcare
dc.relation.ispartofurn:issn:1562-2975
dc.relation.ispartofseriesWorld Journal of Biological Psychiatry
dc.relation.issn1562-2975
dc.rightshttp://purl.org/coar/access_right/c_abf2
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectAntipsychoticsen_US
dc.subjectBipolar disorderen_US
dc.subjectMaintenanceen_US
dc.subjectPharmacotherapyen_US
dc.subjectProphylaxisen_US
dc.titleThe world federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2012 on the long-term treatment of bipolar disorderen_US
dc.typehttps://purl.org/coar/resource_type/c_dcae04bc
dc.type.localRevisión
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dspace.entity.typePublication

Archivos